Skip to main content

Table 2 Patient disposition

From: Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

 

Everolimus 5 mg/day

(n = 12)

Everolimus 10 mg/day

(n = 12)

Ongoing, n (%)

2 (16.7)

1 (8.3)

Discontinued, n (%)

10 (83.3)

11 (91.7)

   Patient withdrew consent

1 (8.3)

2 (16.7)

   Death

0

2 (16.7)

   Disease progression

9 (75.0)

7 (58.3)